Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma-Authors' reply

Manon Allaire^{1

2}, Dominique Thabut^{1

3}

Affiliations

¹ Service d'Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.
² INSERM UMR 1138, Centre de recherche des Cordeliers, Paris, France.
³ Sorbonne Université, INSERM, Centre de recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.

Editorial

Manon Allaire et al. Aliment Pharmacol Ther. 2023 Aug.

. 2023 Aug;58(4):480-481.

doi: 10.1111/apt.17648.

Manon Allaire^{1

2}, Dominique Thabut^{1

3}

¹ Service d'Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.
² INSERM UMR 1138, Centre de recherche des Cordeliers, Paris, France.
³ Sorbonne Université, INSERM, Centre de recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.

No abstract available

Comment on

Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma.
Allaire M, Campion B, Demory A, Larrey E, Wagner M, Rudler M, Roux C, Blaise L, Carrie NG, Thabut D. Allaire M, et al. Aliment Pharmacol Ther. 2023 Aug;58(3):346-356. doi: 10.1111/apt.17599. Epub 2023 Jun 9. Aliment Pharmacol Ther. 2023. PMID: 37300315
Editorial: The use of Baveno VI and VII criteria in patients with hepatocellular carcinoma.
Moctezuma-Velazquez C, Abraldes JG. Moctezuma-Velazquez C, et al. Aliment Pharmacol Ther. 2023 Aug;58(4):478-479. doi: 10.1111/apt.17626. Aliment Pharmacol Ther. 2023. PMID: 37499106 No abstract available.

1. Moctezuma-Velazquez C, Abraldes JG. Editorial: the use of Baveno VI and VII criteria in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:478-79.
1. Allaire M, Campion B, Demory A, Larrey E, Wagner M, Rudler M, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346-56. https://doi.org/10.1111/apt.17599
1. de Franchis R, Faculty BVI. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-52.
1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII-renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-74.
1. Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses…. Liver Int. 2021;41(8):1734-43.